| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Magrolimab manufacturers
- Magrolimab
-
- $745.00
-
2026-07-27
- CAS:2169232-81-7
- Purity: 95.00%
- Supply Ability: 10g
|
| | Magrolimab Basic information |
| Product Name: | Magrolimab | | Synonyms: | Magrolimab;Research Grade Magrolimab(DHG17601);Magrolimab (anti-CD47);Hu5F9-G4|||Magrolimab (anti-CD47);Research Grade Magrolimab;Immunoglobulin G4[225-proline], anti-(human CD47 antigen) (human-Mus musculus monoclonal Hu5F9-G4 γ4-chain), disulfide with human-Mus musculus monoclonal Hu5F9-G4 κ-chain, dimer (ACI) | | CAS: | 2169232-81-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Magrolimab Structure]() |
| | Magrolimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Magrolimab Usage And Synthesis |
| Uses | Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3]. | | in vivo | Magrolimab (12-100 μg; once daily; 10 days; i.p.) exhibits anti-tumor activity in mice with Ewing's sarcoma[1].
Magrolimab (250 μg; once every two days; 7 weeks; i.p.) combined with trastuzumab (HY-P9907) can eliminate HER2 positive breast cancer cells in breast cancer mice and overcome the tolerance of trastuzumab[2]. | Animal Model: | Humanized and non-humanized ES xenograft NSG-SGM3 mice[1]. | | Dosage: | 12-100 μg | | Administration: | Intraperitoneal injection (i.p.); once daily; 10 days | | Result: | Inhibited tumor growth and lung metastasis, and prolonged animal survival time. |
| Animal Model: | 4-8 weeks old NSG female breast cancer mouse model[2]. | | Dosage: | 250 μg | | Administration: | Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice) | | Result: | Restricted the Growth of HER2 ADCC-Tolerant Tumors. |
| | References | [1] Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. DOI:10.3389/fimmu.2023.1277987
[2] Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. DOI:10.1073/pnas.2026849118
[3] Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. DOI:10.1016/j.lfs.2023.121790 |
| | Magrolimab Preparation Products And Raw materials |
|